

India

ADD (no change)

Consensus ratings*: Bo	Buy 9 Hold 3 Sell 3
Current price:	Rs947
Target price:	Rs1,100
Previous target:	Rs1,050
Up/downside:	16.2%
InCred Research / Conse	ensus: 16.0%
Reuters:	UTIA.NS
Bloomberg:	UTIAM IN
Market cap:	US\$1,447m
	Rs120,570m
Average daily turnover:	US\$2.1m
	Rs178.1m
Current shares o/s:	0.0m
Free float:	46.0%
*Source: Bloomberg	

Key changes in this note

➤ The overall market share for UTI AMC dipped to ~5.37% against ~5.54% whereas the share of equity funds dipped to ~3.68% vs. ~3.98% as of Dec 2023.



		Source: B	loomberg
Price performance	1M	ЗМ	12M
Absolute (%)	15.4	10.3	42.2
Relative (%)	12.5	4.9	15.4
Major shareholders		9	% held
T ROWE PRICE			23.0

_					_			
D	00	02	rc	h	۸n	alı	vst	(e)

PNB

SBI



Jignesh SHIAL

T (91) 22 4161 1547

E jignesh.shial@incredresearch.com

Meghna LUTHRA

T (91) 22 4161 1500

E meghna.luthra@incredresearch.com

Rishabh JOGANI

T (91) 02241611569

E rishabh.jogani@incredresearch.com

UTI AMC

Loss of market share is an area of concern

- UTI AMC reported 4Q PAT of Rs1.6bn, below our estimate of Rs2.2bn, amid pressure on revenue yields (-2bp qoq) & elevated expenses (+7% qoq).
- Overall market share for UTI AMC dipped to ~5.37% against ~5.54% whereas the share of equity funds declined to ~3.68% vs. ~3.98% as of end-Dec 2023.
- We like UTI AMC amid its steady inflow, rising operating efficiency and favourable risk-reward ratio. Retain ADD trating with a higher TP of Rs1,100.

Profitability impacted by lower revenue yields, higher expenses

UTI AMC reported 4QFY24 PAT of Rs1.81bn (-11.8% qoq), lower than our estimate of Rs2.2bn, due to lower revenue yields as the growth in better-yield equity AUM (+20.3% yoy) was slower than the growth in low-yield ETF AUM (+39.3% yoy) in FY24. The consistent loss of market share in equity fund AUM continues to remain a cause of concern as the company needs to address the same to gain yield momentum. The company also reported a qoq spurt in operating expenses by ~7% amid elevated employee expenses, which grew by ~11% sequentially. The company's management has been trying to moderate operating expenses, but the actual trend continues to remain adverse.

Market share trend disappointing across portfolios

UTI AMC reported a decline in overall market share sequentially to ~5.37% against ~5.54% in Dec 2023 as mutual fund QAAUM stood at Rs2.91tr (+21.8% yoy) as of Mar 2024. Overall equity fund AUM of the company grew by ~5.1% yoy whereas the hybrid fund declined by ~20.2% yoy. This resulted in a loss in equity fund market share to ~3.68% against ~3.98% last quarter. The company witnessed a marginal improvement in debt fund AUM to ~3.24% against ~3.16% in Dec 2023 and similarly, the market share in exchange traded funds or ETFs improved to ~13.2% against ~13.1% in Dec 2023.

Privatization on the cards - chances of stake acquisition from PSBs

Post-IPO, T Rowe Price International (a global investment management firm) is the largest shareholder with ~23% stake in UTI AMC. T Rowe Price also owns a major stake in UTI Trustee Company. With the rising importance of financial savings among Indian households along with under-penetration and concentrated business model of mutual funds, the outlook for AMCs in India remains buoyant. Considering improving efficiency of UTI AMC, T Rowe Price (already being an investment manager) can opt to buy out majority stake from public sector banks or PSBs (the easiest route) and can become the promoter.

Outlook and valuation

15.0

10.0

We like UTI AMC considering its schemes' improving performance leading to steady inflow and healthy AUM, rationalization of operating expenses strengthening operating performance and a favourable risk-reward ratio. We retain ADD rating on the stock with a higher target price of Rs1,100 (Rs1,050 earlier), corresponding to ~13.4x FY26F EPS. Key downside risks: Lower growth and weak yields impacting profitability.

Financial Summary	Mar-23A	Mar-24A	Mar-25F	Mar-26F	Mar-27F
Total Non-Interest Income (Rsm)	12,669	17,370	20,609	24,054	28,306
Operating Revenue (Rsm)	12,901	17,447	20,700	24,160	28,426
Total Provision Charges (Rsm)	0	0	0	0	0
Net Profit (Rsm)	4,374	7,657	8,851	10,419	12,171
Core EPS (Rs)	34.46	60.26	69.66	82.00	95.79
Core EPS Growth	(18%)	75%	16%	18%	17%
FD Core P/E (x)	27.49	15.72	13.60	11.55	9.89
DPS (Rs)	22.00	22.00	35.00	40.00	50.00
Dividend Yield	2.32%	2.32%	3.69%	4.22%	5.28%
BVPS (Rs)	304.8	345.4	382.9	427.7	476.4
P/BV (x)	3.11	2.74	2.47	2.22	1.99
ROE	11.7%	18.5%	19.1%	20.2%	21.2%
% Change In Core EPS Estimates					
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS




Figure 1: Quarterly results s	ummary									
Rs m	1QFY23	2QFY23	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	YoY (%)	QoQ (%
Revenue from operations	2,931	4,358	2,952	3,007	4,678	4,041	4,491	4,161	38.4%	-7.3%
Other income	129	41	-18	80	8	15	12	42		
Total revenue (Rs m)	3,060	4,399	2,934	3,087	4,686	4,056	4,502	4,203	36.2%	-6.6%
Total expenditure	1,995	1,774	1,910	1,913	1,802	1,858	1,895	2,024	5.8%	6.8%
Cost to Income (%)	65.2%	40.3%	65.1%	62.0%	38.4%	45.8%	42.1%	48.1%		
Profit before tax	1,065	2,626	1,024	1,174	2,884	2,198	2,607	2,180	85.6%	-16.4%
Tax	121	597	424	317	540	370	573	365	15.1%	-36.3%
Tax rate (%)	22.9%	22.9%	22.9%	22.9%	22.9%	22.9%	22.9%	22.9%		
Profit after tax	944	2,028	600	857	2,344	1,828	2,034	1,814	111.7%	-10.8%
QAAUM (Rs tn)	2.24	2.34	2.41	2.39	2.48	2.67	2.73	2.91	21.8%	6.6%
							SOURCE: IN	CRED RESEAR	RCH, COMPAN	NY REPORTS

Y/E Mar (Rs m)		FY25F			FY26F			FY27F	
	Earlier	Revised	% change	Earlier	Revised	% change	Earlier	Revised	% change
Revenue from operations	17,850	20,700	16.0%	20,017	24,160	20.7%	NA	28,426	NA
PAT	7,283	8,851	21.5%	8,613	10,419	21.0%	NA	12,171	NA
EPS (Rs)	57.4	69.7	21.4%	67.9	82.0	20.8%	NA	95.8	NA
Dividend payout (%)	80.0	50.0	-37.5%	80.0	50.0	-37.5%	NA	50.0	NA
QAAUM (Rs tn)	3.2	3.4	7.8%	3.7	4.1	10.5%	NA	4.9	NA



BY THE NUMBERS





Profit & Loss					
(Rsm)	Mar-23A	Mar-24A	Mar-25F	Mar-26F	Mar-27F
Net Interest Income					
Total Non-Interest Income	12,669	17,370	20,609	24,054	28,306
Operating Revenue	12,901	17,447	20,700	24,160	28,426
Total Non-Interest Expenses					
Pre-provision Operating Profit	5,856	9,868	11,664	13,824	16,070
Total Provision Charges					
Operating Profit After Provisions	5,856	9,868	11,664	13,824	16,070
Pretax Income/(Loss) from Assoc.					
Operating EBIT (incl Associates)	5,856	9,868	11,664	13,824	16,070
Non-Operating Income/(Expense)					
Profit Before Tax (pre-EI)	5,856	9,868	11,664	13,824	16,070
Exceptional Items					
Pre-tax Profit	5,856	9,868	11,664	13,824	16,070
Taxation	(1,459)	(1,848)	(2,449)	(3,041)	(3,535)
Consolidation Adjustments & Others					
Exceptional Income - post-tax					
Profit After Tax	4,397	8,020	9,214	10,783	12,535
Minority Interests	(23)	(364)	(364)	(364)	(364)
Pref. & Special Div					
FX And Other Adj.					
Net Profit	4,374	7,657	8,851	10,419	12,171
Recurring Net Profit					

Balance Sheet Employment					
(Rsm)	Mar-23A	Mar-24A	Mar-25F	Mar-26F	Mar-27F
Gross Loans/Cust Deposits					
Avg Loans/Avg Deposits					
Avg Liquid Assets/Avg Assets	9.3%	7.1%	6.9%	8.1%	8.1%
Avg Liquid Assets/Avg IEAs					
Net Cust Loans/Assets					
Net Cust Loans/Broad Deposits					
Equity & Provns/Gross Cust Loans					
Asset Risk Weighting					
Provision Charge/Avg Cust Loans					
Provision Charge/Avg Assets					
Total Write Offs/Average Assets					

SOURCE: INCRED RESEARCH, COMPANY REPORTS



BY THE NUMBERS...cont'd

Balance Sheet					
(Rsm)	Mar-23A	Mar-24A	Mar-25F	Mar-26F	Mar-27F
Total Gross Loans					
Liquid Assets & Invst. (Current)					
Other Int. Earning Assets					
Total Gross Int. Earning Assets					
Total Provisions/Loan Loss Reserve					
Total Net Interest Earning Assets					
Intangible Assets					
Other Non-Interest Earning Assets	2,147	3,117	3,165	3,216	3,268
Total Non-Interest Earning Assets	5,699	5,896	5,999	6,106	6,217
Cash And Marketable Securities	3,572	3,200	4,501	5,468	5,390
Long-term Investments	32,479	44,283	47,826	52,609	58,922
Total Assets	41,751	53,379	58,326	64,182	70,528
Customer Interest-Bearing Liabilities					
Bank Deposits					
Interest Bearing Liabilities: Others					
Total Interest-Bearing Liabilities					
Banks Liabilities Under Acceptances					
Total Non-Interest Bearing Liabilities	3,071	3,678	3,827	3,983	4,147
Total Liabilities	3,071	3,678	3,827	3,983	4,147
Shareholders Equity	38,680	43,882	48,649	54,349	60,531
Minority Interests		5,850	5,850	5,850	5,850
Total Equity	38,680	49,732	54,499	60,199	66,381

Key Ratios					
	Mar-23A	Mar-24A	Mar-25F	Mar-26F	Mar-27F
Total Income Growth					
Operating Profit Growth	85.1%	35.2%	18.6%	16.7%	17.7%
Pretax Profit Growth	(11%)	69%	18%	19%	16%
Net Interest To Total Income					
Cost Of Funds					
Return On Interest Earning Assets					
Net Interest Spread					
Net Interest Margin (Avg Deposits)					
Net Interest Margin (Avg RWA)					
Provisions to Pre Prov. Operating Profit					
Interest Return On Average Assets					
Effective Tax Rate	24.9%	18.7%	21.0%	22.0%	22.0%
Net Dividend Payout Ratio	63.8%	36.5%	50.2%	48.8%	52.2%
Return On Average Assets	10.72%	16.10%	15.85%	17.01%	18.07%

SOURCE: INCRED RESEARCH, COMPANY REPORTS



DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd.(formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. Whilst every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which are believed to be accurate and complete and obtained through reliable public or other non-confidential sources at the time made. (Information barriers and other arrangements may be established where necessary to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short term views etc.) that are inconsistent with and reach different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report



	Analyst/ Relative	Entity/ Associates
any financial interests in the company covered in this report (subject company) and nature of such financial interest	NO	NO
actual/beneficial ownership of 1% or more in securities of the subject company at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;	NO	NO
any other material conflict of interest at the time of publication of the research report or at the time of public appearance	NO	NO
received any compensation from the subject company in the past twelve months for investment banking or merchant banking or brokerage services or investment advisory or depository or distribution from the subject company in the last twelve months for products/services other than investment banking or merchant banking or broker- age services or investment advisory or depository or distribution from the subject company in the last twelve months	NO	NO
managed or co-managed public offering of securities for the subject company in the last twelve months	NO	NO
received any compensation or other benefits from the subject company or third party in connection with the research report	NO	NO
served as an officer, director or employee of the subject company	NO	NO
been engaged in market making activity for the subject company	NO	NO

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in thisreport and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.